Preparation of a pharmaceutical intermediate: An example of how inherent safety can be maximised during the early stages of process development

被引:0
|
作者
Hallam, S [1 ]
Wilkinson, P [1 ]
机构
[1] AstraZeneca, Proc Safety Grp, Macclesfield SK10 2NA, Cheshire, England
来源
HAZARDS XVI: ANALYSING THE PAST, PLANNING THE FUTURE | 2001年 / 148期
关键词
inherent safety;
D O I
暂无
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
An inherently safe process has been defined as one which by virtue of its design will not generate a hazard if a fault occurs. Whilst inherent safety has traditionally been pursued by working with the principles of substitution, minimisation, attenuation and simplification 1, it is often very difficult, if not impossible, to make all processes inherently safe. In this situation the goal then becomes one of making the process as inherently safe as possible. The purpose of this paper is to show, by reference to the synthesis of a pharmaceutical intermediate, how it is possible to make very significant increases in the level of inherent safety within a process providing thermal stability and kinetic data is available.
引用
收藏
页码:305 / 309
页数:5
相关论文
共 21 条
  • [1] Development of hazard prevention strategies for inherent safety assessment during early stage of process design
    Ahmad, Syaza I.
    Hashim, Haslenda
    Hassim, Mimi H.
    Rashid, Roslina
    PROCESS SAFETY AND ENVIRONMENTAL PROTECTION, 2019, 121 : 271 - 280
  • [2] Measuring inherent safety, health and environmental characteristics early in process development
    Hendershot, DC
    PROCESS SAFETY PROGRESS, 1997, 16 (02) : 78 - 79
  • [3] Measuring inherent safety, health and environmental characteristics early in process development
    Hendershot, Dennis C.
    Process Safety Progress, 16 (02): : 78 - 79
  • [4] Tools for an enhanced solvent properties screening in the early stages of pharmaceutical process development
    Perez-Vega, S.
    Nieva-de la Hidalga, A.
    Sharratt, P. N.
    JOURNAL OF LOSS PREVENTION IN THE PROCESS INDUSTRIES, 2014, 29 : 300 - 312
  • [5] Development of a general inherent safety assessment tool at early design stage of chemical process
    Zhu, Jiaxing
    Liu, Zixuan
    Cao, Zhengrong
    Han, Xiaoyi
    Hao, Lin
    Wei, Hongyuan
    PROCESS SAFETY AND ENVIRONMENTAL PROTECTION, 2022, 167 : 356 - 367
  • [6] An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137-A successful approach
    Petzoldt, Christine
    Bley, Oliver
    Byard, Stephen J.
    Andert, Doris
    Baumgartner, Bruno
    Nagel, Norbert
    Tappertzhofen, Christoph
    Feth, Martin Philipp
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 86 (03) : 337 - 350
  • [7] Analytical hierarchy processes (AHP) for the selection of solvents in early stages of pharmaceutical process development
    Perez-Vega, S.
    Peter, Senior
    Salmeron-Ochoa, I.
    Nieva-de la Hidalga, A.
    Sharratt, P. N.
    PROCESS SAFETY AND ENVIRONMENTAL PROTECTION, 2011, 89 (04) : 261 - 267
  • [8] A graphical method for assessing inherent safety during research and development phase of process design
    Ahmad, Syaza I.
    Hashim, Haslenda
    Hassim, Mimi H.
    JOURNAL OF LOSS PREVENTION IN THE PROCESS INDUSTRIES, 2016, 42 : 59 - 69
  • [9] Assessing safety, health, and environmental impact early during process development
    Koller, G
    Fischer, U
    Hungerbühler, K
    INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 2000, 39 (04) : 960 - 972
  • [10] How Can I Trust AI? : Extending a UXer-AI Collaboration Process in the Early Stages
    Yoon, Harin
    Oh, Changhoon
    Jun, Soojin
    EXTENDED ABSTRACTS OF THE 2024 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, CHI 2024, 2024,